Trial Profile

A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 13 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalzanemdor
Indications Huntington's disease
Focus Adverse reactions; Therapeutic Use
Acronyms PURVIEW
Sponsors Sage Therapeutics; Supernus Pharmaceuticals

Most Recent Events

17 Dec 2025 Protocol has been amended(Study design and time frame of the primary endpoint).
17 Dec 2025 Actual primary completion date changed from 10 Jan 2025 to 20 Jan 2025.
04 Feb 2025 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com